Reata Pharmaceuticals, Inc. - (RETA): Price and Financial Metrics

Reata Pharmaceuticals, Inc. - (RETA)

Today's Latest Price: $147.02 USD

0.68 (-0.46%)

Updated Aug 3 12:53pm

Add RETA to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 213 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

RETA Stock Summary

  • RETA's price/sales ratio is 253.99; that's higher than the P/S ratio of 98.34% of US stocks.
  • Over the past twelve months, RETA has reported earnings growth of 208.28%, putting it ahead of 93.8% of US stocks in our set.
  • As for revenue growth, note that RETA's revenue has grown -30.62% over the past 12 months; that beats the revenue growth of merely 6.49% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Reata Pharmaceuticals Inc are VBIV, ACRS, CTIC, OLED, and MNTA.
  • RETA's SEC filings can be seen here. And to visit Reata Pharmaceuticals Inc's official web site, go to
RETA Daily Price Range
RETA 52-Week Price Range

RETA Stock Price Chart Technical Analysis Charts

RETA Price/Volume Stats

Current price $147.02 52-week high $257.96
Prev. close $147.70 52-week low $70.00
Day low $143.45 Volume 84,028
Day high $149.50 Avg. volume 362,193
50-day MA $154.37 Dividend yield N/A
200-day MA $178.25 Market Cap 4.89B

Reata Pharmaceuticals, Inc. - (RETA) Company Bio

Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing product candidates that modulate the activity of key regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with various serious or life-threatening diseases. The company was founded in 2002 and is based in Irving, Texas.

RETA Latest News Stream

Event/Time News Detail
Loading, please wait...

RETA Latest Social Stream

Loading social stream, please wait...

View Full RETA Social Stream

Latest RETA News From Around the Web

Below are the latest news stories about Reata Pharmaceuticals Inc that investors may wish to consider to help them evaluate RETA as an investment opportunity.

Reata Announces the Appointment of Martin W. Edwards, M.D. to Its Board of Directors

PLANO, Texas, July 30, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced the appointment of Martin W. Edwards, M.D. to its Board of Directors, effective August 3, 2020.  Since 2003, Dr. Edwards has held various positions at Novo Holdings, a life sciences investment firm, and most recently, he has served as a part-time Senior Partner.  Earlier in his career, he was Corporate VP and Global Head of Drug Development for Novo Nordisk, where he led all aspects of pre-clinical and clinical drug development.  Dr. Edwards currently serves on the board of directors of three publicly traded pharmaceutical companies, Inozyme Pharma, Inc., Kalvista Pharmaceuticals, Inc., and Verona Pharm...

Yahoo | July 30, 2020

Did Hedge Funds Make The Right Call On Reata Pharmaceuticals, Inc. (RETA) ?

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]

Yahoo | July 13, 2020

Reata Announces Promotion and New Hires For Key Leadership Roles

Colin J. Meyer, MD has been promoted to the newly created position of Chief Research and Development Officer and Executive Vice President. In this role, Dr. Meyer will be responsible for the strategic direction of the Company’s research, development, and clinical functions, with a focus on advancing the development of Reata’s robust product pipeline.

Yahoo | July 7, 2020

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Reata Pharmaceuticals, Inc.- RETA

New York, New York--(Newsfile Corp. - July 3, 2020) -  Levi & Korsinsky announces it has commenced an investigation of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) concerning possible breaches of fiduciary duty. To obtain additional information, go to: contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500. There is no cost or obligation to you.Levi & Korsinsky is a nationally recognized firm with offices in New York, Connecticut, ...

Yahoo | July 3, 2020

INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Reata Pharmaceuticals, Inc. for Potential Breach of Fiduciary Duty Claims

NEW YORK, NY / ACCESSWIRE / June 30, 2020 / Fields Kupka & Shukurov LLP is investigating potential breach of fiduciary duty claims involving the board of directors of Reata Pharmaceuticals, Inc. (NASDAQ: ...

Yahoo | June 30, 2020

Read More 'RETA' Stories Here

RETA Price Returns

1-mo N/A
3-mo -6.70%
6-mo -35.68%
1-year 63.59%
3-year 411.73%
5-year N/A
YTD -28.08%
2019 264.40%
2018 98.09%
2017 29.73%
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9272 seconds.